| gap-debate-20260403- | Does TFEB dysfunction cause neurodegeneration or represent a compensatory respon | partially_addressed | 0.90 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-debate-20260403- | How do neurodegeneration gene expression patterns in SEA-AD differ from other po | partially_addressed | 0.75 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-debate-20260403- | Which cell types show the most significant expression changes for neurodegenerat | partially_addressed | 0.82 | 0.00 | 2026-04-04 | 0 | | neurodegeneration |
| gap-debate-20260403- | Unable to extract research questions - transcript appears to be empty | partially_addressed | 0.00 | 0.00 | 2026-04-04 | 0 | | methodology |
| gap-epigenetic-repro | Epigenetic reprogramming in aging neurons | partially_addressed | 0.85 | 0.71 | 2026-04-02 | 1 | 2026-04-02 | neurodegeneration |
| gap-senescent-cleara | Senescent cell clearance as neurodegeneration therapy | resolved | 0.95 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-crispr-neurodege | CRISPR-based therapeutic approaches for neurodegenerative diseases | partially_addressed | 0.93 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-ev-ad-biomarkers | Extracellular vesicle biomarkers for early AD detection | partially_addressed | 0.92 | 0.85 | 2026-04-02 | 1 | 2026-04-12 | neurodegeneration |
| gap-aging-mouse-brai | Gene expression changes in aging mouse brain predicting neurodegenerative vulner | resolved | 0.92 | 0.69 | 2026-04-02 | 0 | | neurodegeneration |
| gap-aging-mouse-brai | Gene expression changes in aging mouse brain predicting neurodegenerative vulner | resolved | 0.92 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-immune-atlas-neu | Immune atlas neuroinflammation analysis in neurodegeneration | partially_addressed | 0.95 | 0.70 | 2026-04-02 | 0 | | neuroinflammation |
| gap-aging-mouse-brai | Gene expression changes in aging mouse brain predicting neurodegenerative vulner | resolved | 0.92 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-aging-mouse-brai | Gene expression changes in aging mouse brain predicting neurodegenerative vulner | resolved | 0.92 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-aging-mouse-brai | Gene expression changes in aging mouse brain predicting neurodegenerative vulner | partially_addressed | 0.92 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-tau-propagation- | Tau propagation mechanisms and therapeutic interception points | partially_addressed | 0.90 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-microglial-subty | Microglial subtypes in neurodegeneration — friend vs foe | partially_addressed | 0.88 | 0.70 | 2026-04-02 | 0 | | neuroscience |
| gap-tau-prop-2026040 | Tau propagation mechanisms and therapeutic interception points | partially_addressed | 0.95 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-20260402-003115 | Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi | resolved | 0.90 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-20260402-003058 | Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidi | partially_addressed | 0.90 | 0.72 | 2026-04-02 | 0 | | neurodegeneration |
| gap-v2-5d0e3052 | Metabolic reprogramming in neurodegenerative disease | partially_addressed | 0.83 | 0.67 | 2026-04-02 | 0 | | neurodegeneration |
| gap-seaad-v4-2026040 | Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data) | resolved | 0.98 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-seaad-v3-2026040 | Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data) | partially_addressed | 0.98 | 0.72 | 2026-04-02 | 0 | | neurodegeneration |
| gap-seaad-v2-2026040 | Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2) | partially_addressed | 0.98 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-seaad-2026040202 | Cell type vulnerability in Alzheimer's Disease (SEA-AD data) | partially_addressed | 0.95 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| 26abc5e5f9f2 | Circuit-level neural dynamics in neurodegeneration | partially_addressed | 0.95 | 0.70 | 2026-04-02 | 0 | | neuroscience |
| gap-v2-18cf98ca | Sleep disruption as cause and consequence of neurodegeneration | partially_addressed | 0.84 | 0.65 | 2026-04-02 | 0 | | neurodegeneration |
| gap-v2-ee5a5023 | Perivascular spaces and glymphatic clearance failure in AD | partially_addressed | 0.87 | 0.68 | 2026-04-02 | 0 | | neurodegeneration |
| gap-v2-bc5f270e | Epigenetic clocks and biological aging in neurodegeneration | partially_addressed | 0.83 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-v2-89432b95 | Mitochondrial transfer between astrocytes and neurons | partially_addressed | 0.85 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-v2-691b42f1 | Synaptic pruning by microglia in early AD | partially_addressed | 0.88 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-v2-68d9c9c1 | RNA binding protein dysregulation across ALS FTD and AD | partially_addressed | 0.86 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-012 | Digital biomarkers and AI-driven early detection of neurodegeneration | partially_addressed | 0.84 | 0.00 | 2026-04-02 | 0 | | neurodegeneration |
| gap-013 | Senolytic therapy for age-related neurodegeneration | partially_addressed | 0.86 | 0.00 | 2026-04-02 | 0 | | neurodegeneration |
| gap-011 | Autophagy-lysosome pathway convergence across neurodegenerative diseases | partially_addressed | 0.87 | 0.70 | 2026-04-02 | 0 | | neurodegeneration |
| gap-014 | Neuroinflammation resolution mechanisms and pro-resolving mediators | partially_addressed | 0.83 | 0.71 | 2026-04-02 | 0 | | neurodegeneration |
| gap-010 | APOE4 structural biology and therapeutic targeting strategies | partially_addressed | 0.91 | 0.66 | 2026-04-02 | 0 | | neurodegeneration |
| gap-009 | Microglia-astrocyte crosstalk amplification loops in neurodegeneration | partially_addressed | 0.89 | 0.69 | 2026-04-02 | 0 | | neurodegeneration |
| gap-001 | TREM2 agonism vs antagonism in DAM microglia | resolved | 0.92 | 0.70 | 2026-04-01 | 0 | | neurodegeneration |
| gap-008 | Blood-brain barrier transport mechanisms for antibody therapeutics | partially_addressed | 0.91 | 0.70 | 2026-04-01 | 0 | | neurodegeneration |
| gap-006 | TDP-43 phase separation therapeutics for ALS-FTD | partially_addressed | 0.83 | 0.71 | 2026-04-01 | 0 | | neurodegeneration |
| gap-002 | GBA-alpha-synuclein bidirectional loop in Parkinson's | partially_addressed | 0.88 | 0.69 | 2026-04-01 | 0 | | neurodegeneration |
| gap-003 | Gut-brain axis metabolites in early AD pathogenesis | partially_addressed | 0.85 | 0.70 | 2026-04-01 | 0 | | neurodegeneration |
| gap-005 | 4R-tau strain-specific spreading patterns in PSP vs CBD | partially_addressed | 0.87 | 0.68 | 2026-04-01 | 0 | | neurodegeneration |
| gap-007 | Astrocyte reactivity subtypes in neurodegeneration | partially_addressed | 0.86 | 0.70 | 2026-04-01 | 0 | | neurodegeneration |
| gap-004 | Selective vulnerability of entorhinal cortex layer II neurons in AD | partially_addressed | 0.90 | 0.70 | 2026-04-01 | 0 | | neurodegeneration |